Colloid and interface science in pharmaceutical research and development / Hiroyuki Ohshima, Kimiko Makino.

Format
Book
Language
English
Εdition
First edition.
Published/​Created
Amsterdam : Elsevier, 2014.
Description
xv, 516 pages : illustrations ; 24 cm

Availability

Copies in the Library

Location Call Number Status Location Service Notes
Lewis Library - Stacks QD549 .C65 2014 Browse related items Request

    Details

    Subject(s)
    Editor
    Bibliographic references
    Includes bibliographical references and index.
    Contents
    • Note continued: 13.2. Basic Character of PEG
    • 13.3. Biofouling Resistant Mechanism on PEG Modified Surface Based on the Molecular Structure
    • 13.4. PEGylation
    • 13.4.1. PEGylation for Biomolecules
    • 13.4.2. PEGylation for Solid Substrate
    • 13.5. PEGylated Block Copolymer for Nanostructured Materials and Surfaces
    • 13.6. PEGylated for the Fabrication of High-Performance Metal Nanoparticles
    • 13.6.1. Metal Nanoparticle for Biological System Detection
    • 13.6.2. PEGylation of Metal Nanoparticles for their Bioanalytical Applications
    • 13.6.3. PEGylated Block Copolymer for Nanoreactor
    • 13.6.4. PEGylated Copolymer with Multivalent Anchor to Metal Surface
    • 13.7. Conclusion
    • References
    • ch. 14 PEGylated Polymer Micelles for Anticancer Drug Delivery Carrier
    • 14.1. Introduction
    • 14.2. Polymer Micelles as an Anticancer Drug Delivery Carrier
    • 14.3. PEG-b-PVBP Block Copolymer-Based PEGylated Polymer Micelles (DOX@PNP)
    • 14.4. Enhanced Intracellular Drug Delivery of DOX@PNPs in Multidrug-Resistant (MDR) Cancer Cells
    • 14.5. Conclusion
    • ch. 15 Convective Diffusion of Nanoparticles to Regional Lymph Nodes from the Epithelial Barrier
    • 15.1. Introduction
    • 15.2. Modelling Fluid Flow in Interstitium Around Initial Capillary Initiated by Intrinsic Pump
    • 15.3. Distribution of Fluid Velocity in the Interstitium Between the EB and an Adjacent ILC
    • 15.4. Time of Transport Through Interstitium
    • 15.5. Discussion
    • 15.6. Summary and Conclusions
    • ch. 16 Highly Fluorinated Colloids in Drug Delivery and Imaging
    • 16.1. Properties of F-Compounds
    • 16.1.1. Fluorous Phase
    • 16.1.2. Encapsulation and Stabilisation
    • 16.1.3. High Oxygen Solubility
    • 16.1.4. Imaging
    • 16.1.5. Toxicity
    • 16.2. Nano-Sized F-Colloids
    • 16.2.1. Controlled Release of Hydrophobic Drugs
    • 16.2.2. Ionic F-Colloids
    • 16.2.3. Paramagnetic Drug Delivery Vehicles
    • 16.2.4. Pulmonary Delivery, Research Tools, and Other Diverse Applications
    • 16.3. Micron-Sized F-Colloids
    • 16.3.1. Microbubbles
    • 16.3.2. Emulsions
    • 16.3.3. Pulmonary Applications
    • 16.3.4. Current F-Colloidal Pharmaceuticals
    • 16.3.5. Conclusion
    • ch. 17 Cell-Penetrating Peptide Polymer Nanomicelle-Based Cytosol-Sensitive Nucleotide Delivery Systems
    • 17.1. Introduction
    • 17.2. Overview of Cytosol-Sensitive Polymer for Gene Delivery
    • 17.2.1. Disulphide-Linked Cationic Polymer Carriers
    • 17.2.2. Disulphide-Crosslinked Polypeptide
    • 17.3. Cytoplasm-Sensitive Artificial CPP Micelles
    • 17.3.1. Cell-Penetrating Peptides
    • 17.3.2. Artificial CPP Carrier
    • 17.4. Conclusion
    • Acknowledgements
    • ch. 18 Cycloamylose-Based Nanocarriers as a Nucleic Acid Delivery System
    • 18.1. Introduction
    • 18.2. Polymer-Based Nucleic Acid Nanocarriers
    • 18.3. Cycloamylose
    • 18.4. Functionalized Cycloamylose for siRNA Delivery
    • 18.5. Functional Cycloamylose for pDNA Delivery
    • 18.6. Cycloamylose Nanogel Gene Delivery: Enhancing Endosomal Escape Using Phospholipase A2
    • 18.7. Conclusion
    • ch. 19 Colloidal Drug Delivery System for Brain-Targeting Therapy
    • 19.1. Introduction
    • 19.2. Colloidal Drug Delivery System in Pharmaceutical Application
    • 19.2.1. Particle Size
    • 19.2.2. Particle Shape
    • 19.2.3. Surface Charge
    • 19.2.4. Targeting Moiety on Particle Surface
    • 19.3. Colloidal Formulation for Treating Brain Pathology and Disease
    • 19.3.1. Acute Ischaemic Stroke
    • 19.3.2. Brain Tumour
    • 19.3.3. Alzheimer's Disease
    • 19.3.4. Parkinson's Disease
    • ch. 20 Colloidal Carriers for Noninvasive Delivery of Insulin
    • 20.1. Introduction
    • 20.2. Noninvasive Routes of Insulin Delivery
    • 20.2.1. Oral Route
    • 20.2.2. Buccal and Sublingual Routes
    • 20.2.3. Nasal Route
    • 20.2.4. Pulmonary Route
    • 20.3. Barriers to Noninvasive Insulin Delivery
    • 20.3.1. The Enzymatie Barrier
    • 20.3.2. The Absorption Barrier
    • 20.3.3. Overcoming the Enzymatic Barrier
    • 20.3.4. Overcoming the Absorption Barrier
    • 20.4. Colloidal Carriers for Noninvasive Insulin Delivery
    • 20.4.1. Liposomes
    • 20.4.2. Microparticles
    • 20.4.3. Nanoparticles
    • 20.4.4. Microemulsions
    • 20.4.5. Uptake of Colloidal Carriers
    • 20.5. Market Status of Noninvasive Insulin Delivery System
    • 20.6. Future Scope
    • ch. 21 Particle Geometry, Charge, and Wettability: The Fate of Nanoparticle-Based Drug Vehicles
    • 21.1. Introduction
    • 21.2. Drug Adsorption
    • 21.2.1. Size and Shape Effects
    • 21.2.2. Drug
    • particle Interaction
    • 21.3. Transport in the Blood Vessels
    • 21.3.1. The Role of Particle Geometry
    • 21.3.2. Surface Charge and Thermodynamics
    • 21.4. Particle Uptake by Tumour Cells
    • 21.4.1. Role of Particle Size and Shape
    • 21.4.2. Surface Charge and Hydrophobicity
    • 21.5. Particle Release and Toxicity
    • ch. 22 Lipid Emulsions and Lipid Vesicles Prepared from Various Phospholipids as Drug Carriers
    • 22.1. Introduction
    • 22.2. Particle Size and Entrapment in Liposomes Prepared with Egg Yolk Lecithins and Hydrogenated Egg Yolk Lecithins
    • 22.2.1. Materials and Methods
    • 22.2.2. Results and Discussion
    • 22.3. Properties of Various PCs as Emulsifiers or Dispersing Agents in Nanoparticle Preparations for Drug Carriers
    • 22.3.1. Materials and Methods
    • 22.3.2. Results and Discussion
    • 22.4. Physicochemical Properties of Structured PC in Drug Carrier Lipid Emulsions
    • 22.4.1. Materials and Methods
    • 22.4.2. Results and Discussion
    • 22.5. Conclusion
    • References.
    • Machine generated contents note: ch. 1 Interaction of Colloidal Particles
    • 1.1. Introduction
    • 1.2. Potential Distribution Around a Charged Surface: The Poisson--Boltzmann Equation
    • 1.2.1. Hard Particle
    • 1.2.2. Soft Particles
    • 1.3. Electrical Double Layer Interaction Between Two Particles
    • 1.3.1. Linear Superposition Approximation
    • 1.3.2. Derjaguin's Approximation
    • 1.4. van der Waals Interaction Between Two Particles
    • 1.4.1. Two Molecules
    • 1.4.2. A Molecule and a Plate
    • 1.4.3. Two Parallel Plates
    • 1.4.4. Two Spheres
    • 1.4.5. Two Cylinders
    • 1.4.6. Two Particles Immersed in a Medium
    • 1.4.7. Two Parallel Plates Covered with Surface Layers
    • 1.5. DLVO Theory of Colloid Stability
    • 1.5.1. Total Interaction Energy Between Two Spherical Particles
    • 1.5.2. Positions of a Potential Maximum and a Secondary Minimum
    • 1.5.3. The Height of a Potential Maximum and the Depth of a Secondary Minimum
    • 1.5.4. Stability Map
    • 1.6. Conclusion
    • ch. 2 Colloid and Interface Aspects of Pharmaceutical Science
    • 2.1. General Introduction
    • 2.2. Disperse Systems ~
    • 2.2.1. Thermodynamic Considerations
    • 2.2.2. Kinetic Stability of Disperse Systems and the General Stabilisation Mechanisms
    • 2.3. Surface Activity and Colloidal Properties of Drugs
    • 2.4. Naturally Occurring Micelle Forming Systems
    • 2.5. Biological Implications of the Presence of Surfactants in Pharmaceutical Formulations
    • 2.6. Solubilised Systems
    • 2.7. Liposomes and Vesicles in Pharmacy
    • 2.8. Stabilisation of Liposomes by Incorporation of Block Copolymers
    • 2.9. Nanoparticles, Drug Delivery and Drug Targetting
    • 2.10. The Reticuloendothelial System
    • 2.11. Influence of Particle Characteristics
    • 2.12. Surface-modified Polystyrene Particles as Model Carriers
    • 2.13. Biodegradable Polymeric Carriers
    • ch. 3 Interracial Properties of Therapeutic Pulmonary Surfactants Studied by Thin Liquid Films
    • 3.1. Introduction
    • 3.2. Thin Liquid Films and Methods for their Experimental Research
    • 3.2.1. Thin Liquid Films: Foam Films, Wetting Films
    • 3.2.2. Microscopic Foam Films and Wetting Films: Methods for their Formation and Study
    • 3.2.3. Micro-Interferometric Method and Pressure Balance Technique
    • 3.3. Black Foam Films
    • 3.3.1. A Model to Study Alveolar Stability and Structure
    • 3.3.2. Method for Lung Maturity Assessment
    • 3.4. Therapeutic Pulmonary Surfactants
    • 3.5. Inhibitory Effect on Therapeutic Pulmonary Surfactants
    • 3.6. Wetting Behaviour of Pulmonary Surfactant Aqueous Solutions
    • 3.6.1. Solid Surfaces with Different Hydrophobicity
    • 3.6.2. Dependence of the Wetting Contact Angles on the Concentration of the Pulmonary Surfactant Aqueous Solution
    • 3.6.3. Thickness of Wetting Films from Pulmonary Surfactant Aqueous Solutions
    • 3.7. Conclusions
    • ch. 4 Surface Interactions in Propellant Driven Metered Dose Inhaler Product Design
    • 4.1. Introduction
    • 4.2. Surfactant Behaviour in Non-Aqueous Solution
    • 4.2.1. Surfactant Alone
    • 4.2.2. Surfactant-Co-Solvent
    • 4.2.3. Surfactant-Particle Surface
    • 4.2.4. Surfactant-Container Surface
    • 4.2.5. Surfactant-Valve
    • 4.3. Particle Behaviour in Non-Aqueous Solution
    • 4.3.1. Particle Suspension
    • 4.3.2. Particle-Particle Interactions
    • 4.3.3. Particle-Container Wall Interaction
    • 4.4. Aerosol Droplet Formation and Dispersion
    • 4.4.1. Formulation Contribution
    • 4.4.2. Actuator Dimensions
    • 4.4.3. Flash Evaporation from the Metering Valve
    • 4.4.4. Droplet Evaporation and Spray Plume Development
    • 4.5. Formulation Development Strategy
    • 4.5.1. Drug Selection
    • 4.5.2. Micronisation
    • 4.5.3. Design Space
    • 4.5.4. Process Development
    • 4.5.5. Experimental Design
    • 4.5.6. Dissolution (Simple, Reproducible Method)
    • 4.5.7. Mathematical Model
    • 4.6. Conclusion
    • ch. 5 Particle-Manufacturing Technology-Based Inhalation Therapy for Pulmonary Diseases
    • 5.1. Introduction
    • 5.2. Pulmonary Diseases
    • 5.2.1. Pulmonary Tuberculosis
    • 5.2.2. Lung Cancer
    • 5.2.3. Chronic Obstructive Pulmonary Disease
    • 5.3. Lung Defence System
    • 5.3.1. Structure
    • 5.3.2. Mucus Layer
    • 5.3.3. Pulmonary Surfactant
    • 5.4. Characteristics of Inhalable Particles
    • 5.4.1. Particle Size
    • 5.4.2. Dispersibility
    • 5.5. Manufacturing Technologies for Production of Inhalable Particles
    • 5.5.1. Milling
    • 5.5.2. Spray-Drying
    • 5.5.3. Encapsulation by Lipids
    • 5.5.4. Freeze-Drying
    • 5.6. Clinical Applications of Inhalable Particles
    • 5.6.1. Pulmonary Tuberculosis Therapy
    • 5.6.2. Nanoparticle-Based Lung Cancer Therapy
    • 5.6.3. Inhalation Therapy for COPD
    • 5.7. Summary
    • ch. 6 QSAR Study for Transdermal Delivery of Drugs and Chemicals
    • 6.1. Introduction
    • 6.2. Viewpoints of the Conventional QSAR
    • 6.3. QSAR Descriptors of Hydrophobicity
    • 6.4. Pharmaceutical Approaches of QSAR
    • 6.5. Thermodynamic Parameters of Dissolution and Melting
    • ch. 7 Nanoparticles for Transdermal Drug Delivery System (TDDS)
    • 7.1. Introduction
    • 7.2. Nanoparticles for Transdermal Drug Delivery
    • 7.3. Combination of Nanoparticle System and IP
    • 7.4. Improved Nanoparticles for Iontophoretic Transdermal Drug Delivery
    • 7.5. Conclusions
    • ch. 8 Interfacial and Colloidal Properties of Emulsified Systems: Pharmaceutical and Biological Perspective
    • 8.1. Introduction
    • 8.2. Types of Emulsion
    • 8.3. Colloidal and Interfacial Properties of Emulsified Systems
    • 8.3.1. Interfacial Properties
    • 8.3.2. Electrical Properties
    • 8.4. Mechanism of Emulsion Formation and Stabilisation
    • 8.4.1. Spontaneous Curvature CO
    • 8.5. Pharmaceutical Aspects of Emulsified Systems
    • 8.5.1. Globule Size and Size Distribution
    • 8.5.2. ζ Potential or Surface Charge
    • 8.6. Emulsifying Agents and their Mechanism of Stabilisation
    • 8.7. Behaviour of Emulsions in Biological Milieu
    • 8.8. Oral Administration
    • 8.8.1. Stability of Emulsion During Transit Through GI Tract
    • 8.9. Parenteral Administration
    • 8.9.1. Interaction with Plasma Proteins and Blood Cells
    • 8.9.2. Pharmacokinetics and Tissue Distribution
    • 8.10. New Class of Emulsifying Agents
    • 8.11. Modifications and Recent Advances in Emulsified Systems As a Drug Delivery Vehicle
    • 8.12. Conclusion
    • ch. 9 Size-Based Characterisation of Nanomaterials by Taylor Dispersion Analysis
    • 9.1. Introduction and Theoretical Aspect
    • 9.1.1. Introduction and Historical Background
    • 9.1.2. TDA: Theoretical Aspect
    • 9.2. Corrections
    • 9.2.1. Corrections Due to Capillary Geometry
    • 9.2.2. Corrections Due to the Mobilisation Pressure Ramp
    • 9.2.3. Corrections Due to the Finite Injected Volume
    • 9.3. Double/Single-Detection Point(s) for TDA
    • 9.4. Polydisperse and Monodisperse Samples: Signal Integration and Average Diffusion Coefficient
    • 9.5. Applications of TDA
    • ch. 10 Peculiarities of Live Cells' Interaction with Micro- and Nanoparticles
    • 10.1. Introduction
    • 10.2. Experiment
    • 10.2.1. Relationship Between Transmembrane and ζ-Potentials: Biospecific Mechanism of DL Formation
    • 10.2.2. Long-range Interactions of Microparticles with Live Cells
    • 10.2.3. Reversible Interaction of Live Cells with Gold Nanoparticles
    • 10.2.4. Gold Nanoparticles Affect Cell Metabolism and Penetrate Inside Cells
    • 10.3. Theory
    • 10.3.1. Micro-Dielectrophoresis
    • 10.3.2. Micro-Diffusiophoresis
    • 10.3.3. Models Explaining Reversibility of the Interaction of Nanoparticles with Live Cells by Movement of Delocalized ions and Related `Electrosmotic Trap'
    • 10.4. Conclusions
    • Appendix General Concepts of Live Cell Electrophysiology
    • ch. 11 Micropatterning of Cell Aggregate in Three Dimension for In Vivo Mimicking Cell Culture
    • 11.1. Introduction
    • 11.2. Cell Patterning Techniques
    • 11.2.1. The Basis of Cellular Patterning; Nonfouling Surface Chemistries
    • 11.2.2. Dry Etching (Plasma Etching)
    • 11.2.3. Cell Assembly for Tissue Engineering
    • 11.2.4. Photolithography
    • 11.2.5. Soft Lithography
    • 11.2.6. Hanging Drop
    • 11.3. Conclusion
    • ch. 12 Adhesion-Dependent Cell Regulation Via Adhesion Molecule, Integrin Therapeutic application of Integrin Activation-Modulating factors
    • 12.1. Eradication of Acute Myelogenous Leukaemia by Combination Therapy of Anticancer Drug with Antiadhesive Peptide FNIII14
    • 12.1.1. Introduction
    • 12.1.2. FNIII14 Abrogates CAM-DR in AML Cells
    • 12.1.3. Molecular Mechanism of CAM-DR Abrogation by FNIII14
    • 12.1.4. Combination Therapy of Peptide FNIII14 with AraC Abrogated Bone Marrow MRD in AML Model Mouse
    • 12.1.5. Effect of the Combination Therapy on Myelosuppression
    • 12.1.6. Conclusion
    • 12.2. Potentiated and Sustained Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation
    • 12.2.1. Introduction
    • 12.2.2. Stimulation with PMA of Cells Adhered on Fibronectin Is Effective for PPF
    • 12.2.3. Identification of Fibronectin Receptor Involved in Adhesion-Dependent PPF Induction with PMA
    • 12.2.4. Signalling Pathway for PMA-Induced PPF on Fibronectin Substrate
    • 12.2.5. Effect of Integrin Activation on PMA-Induced PPF on Fibronectin Substrate
    • 12.2.6. Conclusion
    • 12.3. Concluding Remarks
    • ch. 13 PEGylation for Biocompatible Surface
    • 13.1. Introduction --
    ISBN
    • 9780444626141 ((cloth))
    • 044462614X ((cloth))
    OCLC
    885017210
    Statement on language in description
    Princeton University Library aims to describe library materials in a manner that is respectful to the individuals and communities who create, use, and are represented in the collections we manage. Read more...
    Other views
    Staff view

    Supplementary Information